
    
      This is an open-label, single ascending dose study of BD111 in adult (ages 18 to 70)
      participants with refractory herpetic viral keratitis. Approximately 6 participants will be
      enrolled.BD111 is a novel gene editing product designed to clear Herpes simplex virus type I
      (HSV-1) that results in herpetic stromal keratitis in both acute and recurrent infection
      models which is the leading factor for infectious blindness.

      The follow-up period was 360 days, and the patients will be followed up 3±1 days, 7±2 days,
      30±7 days, 90±14 days, 180±21 days, and 360+31 days after treatment.
    
  